151. Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications
- Author
-
Daniela Zicari, Clelia Mencaroni, Alice Baldi, Sara Baglivo, Giulia Costanza Leonardi, Lucio Crinò, Luca Paglialunga, Biagio Ricciuti, Guido Bellezza, Giulio Metro, and Francesco Grignani
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,Lung Neoplasms ,Synthetic lethality ,Selumetinib ,medicine.medical_treatment ,Adenocarcinoma of Lung ,Antineoplastic Agents ,Adenocarcinoma ,KRAS ,Mutant allele-specific imbalance ,NSCLC ,Prediction ,Prognosis ,Signal transduction ,Targeted therapy ,medicine.disease_cause ,Proto-Oncogene Proteins p21(ras) ,03 medical and health sciences ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Immunology and Allergy ,Molecular Targeted Therapy ,Lung cancer ,neoplasms ,Survival rate ,Oncogene ,business.industry ,Public Health, Environmental and Occupational Health ,Cancer ,medicine.disease ,digestive system diseases ,respiratory tract diseases ,030104 developmental biology ,030220 oncology & carcinogenesis ,Mutation ,Cancer research ,business - Abstract
Lung cancer is the leading cause of cancer deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for 80% of all lung cancers. Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the deadliest cancer-related proteins and plays a pivotal role in the most aggressive and lethal human cancers, including lung adenocarcinoma where it represents one of the most frequently mutated oncogene. Although therapeutic progresses have made an impact over the last decade, median survival for patients with advanced lung cancer remains disappointing, with a 5-year worldwide survival rate of
- Published
- 2016